In The News Posted May 21, 2019 Share Posted May 21, 2019 WESTON, Fla., May 21, 2019 /PRNewswire/ -- ZyVersa Therapeutics, Inc., a clinical stage specialty biopharmaceutical company developing first-in-class drugs for inflammatory and renal diseases, is pleased to announce formation of its inaugural Immunology Scientific Advisory Board comprised ... View the full article Link to comment Share on other sites More sharing options...
Recommended Posts
Archived
This topic is now archived and is closed to further replies.